Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
J Alzheimers Dis. Author manuscript; available in PMC 2010 August 19.
Published in final edited form as:
PMCID: PMC2923835

A Synergistic Dysfunction of Mitochondrial Fission/Fusion Dynamics and Mitophagy in Alzheimer’s Disease


Alzheimer’s disease (AD), the most common form of dementia in the elderly, can have a late-onset sporadic or an early-onset familial origin. In both cases, the neuropathological hallmarks are the same: senile plaques and neurofibrillary tangles. Despite AD having a proteinopathic nature, there is strong evidence for an organelle dysfunction-related neuropathology, namely dysfunctional mitochondria. In this regard, dysfunctional mitochondria and associated exacerbated generation of reactive oxygen species are among the earliest events in the progression of the disease. Since the maintenance of a healthy mitochondrial pool is essential given the central role of this organelle in several determinant cellular processes, mitochondrial dysfunction in AD would be predicted to have profound pluripotent deleterious consequences. Mechanistically, recent reports suggest that mitochondrial fission/fusion and mitophagy are altered in AD and in in vitro models of disease, and since both processes are reported to be protective, this review will discuss the role of mitochondrial fission/fusion and mitophagy in the pathogenesis of AD.

Keywords: Alzheimer’s disease, fission, fusion, mitochondrial dysfunction, mitophagy


Alzheimer’s disease (AD), the most common form of dementia, impacts more than 35 million people worldwide and represents over 50% of autopsy cases and patients with clinical records. The incidence of the disease doubles every 5 years after 65 years of age, with the diagnosis of 1,275 new cases per year per 100,000 persons older than 65 years of age [1]. Clinically, AD is characterized by progressive memory loss, impairments in behavior, language, and visuospatial skills, and culminates in the premature death of the individual typically within 3–9 years after diagnosis. The etiology of AD is not fully understood; it has either a sporadic origin with a late onset, in which the main risk factor is aging, or an early-onset familial form with a genetic origin involving mutations in the amyloid-β protein precursor (AβPP) and presenilin 1 and 2 (PS1 and PS2) genes [2]. Neuropathologically, AD is characterized by a selective neuronal and synaptic loss and the accumulation of extracellular aberrant protein aggregates of amyloid-β (Aβ), usually referred to as senile plaques, and intracellular aggregates of hyperphosphorylated tau protein, usually referred to as neurofibrillary tangles [3]. Aβ peptides are 36 to 43 amino acids in length. Aβ40 is the more abundant monomeric form, but Aβ42 has a greater tendency to aggregate, being the most toxic form of the peptide. Aβ aggregates to form soluble oligomeric species (composed of 2 to 6 peptides) and insoluble fibrils (β-pleated sheets) [1]. It is noteworthy that currently it is believed that the soluble/oligomeric Aβ is the most toxic entity [4,5]. The number of neurofibrillary tangles reflects the severity of AD. In this form, hyperphosphorylated tau is insoluble and aggregates to form paired helical filamentous structures that are thought to impair axonal transport. Intermediate abnormal tau aggregates are cytotoxic [1]. The molecular mechanisms underlying the pathogenesis of AD remain largely unclear, however, several hypotheses are currently being investigated to uncover early events in the development of the disease. The hope is that the discovery of such early events of disease will provide a clinical opportunity for an efficient therapeutic intervention. The different hypotheses include, but are certainly not limited to: the mitochondrial cascade hypothesis [68], oxidative stress [9], cerebrovascular damage [10,11], tau hyperphosphorylation [1214], and the dominating amyloid cascade hypothesis [1517]. This article will position mitochondria center stage and suggest a mitocentric view of AD pathogenesis with other aspects as secondary byproducts of abnormal mitochondrial function. Indeed, the mitochondrial cascade hypothesis implicates these organelles in the formation of Aβ aggregates and hyperphosphorylated tau. According to Swerdlow and Khan [6,7], the authors of this hypothesis, Aβ is unlikely to be the cause of mitochondrial dysfunction in sporadic AD, but rather a downstream product of mitochondrial functional decline with aging. This is further supported by observations that found AβPP and the γ-secretase enzymatic complex present in mitochondria. Similarly, tau phosphorylation is increased by cellular energetic deficits via mechanisms involving the failure of glycogen synthase kinase 3β inhibition (for further reading, see [7]).

Several key physiological functions are attributed to mitochondria, including cellular energetic maintenance, intracellular Ca2+ homeostasis, and cell life and death decisions [18,19]. Since neurons have a reduced glycolytic capacity, they are highly dependent on mitochondrial energy production [20]. Unfortunately, the generation of energy by mitochondria generates toxic byproducts such as reactive oxygen species (ROS) – highly reactive, reduced species of oxygen that are responsible for the oxidative damage of lipids, proteins, and nucleic acids including the mitochondrial components themselves, predisposing to apoptotic cell death [21,22]. Such oxidative injury to mitochondria and other cellular structures accumulates with time, leading to several deleterious effects related with aging and age-related neurodegenerative disorders, as postulated by the free radical theory of aging [2123]. Given the sensitivity of neurons to changes in mitochondrial function [24], it is not surprising that dysfunctional mitochondria are implicated in neuronal function and survival and in neuronal diseases associated with mutations in mitochondrial genes [25]. Indeed, mitochondrial dysfunction and oxidative injury have a recognized role in the pathophysiology of AD [7,26, 27], suggesting they might have an early role in the development of the disease [2732]. However, the mechanisms underlying mitochondrial dysfunction in AD and how mitochondrial dysfunction contributes to disease pathogenesis remains unclear. Nonetheless, significant recent findings demonstrate the involvement of mitochondrial fusion/fission and mitophagy in the disease process. Mitochondrial fission and fusion processes, besides maintaining a normal mitochondrial distribution and morphology, provide a mechanism for the segregation of mitochondrial-damaged constituents waiting to undergo mitophagic elimination [3335]. This review will discuss the role of mitochondrial fission/fusion events and their relation with the elimination of damaged mitochondria by mitophagy, emphasizing the importance of these processes in AD.


The mitochondrial electron respiratory chain is responsible, ultimately, for reducing molecular oxygen to water creating a proton gradient across the membrane and electron transport through the respiratory complexes; however, during this efficient process there is a leak of some electrons, which prematurely reduce oxygen to generate ROS [36]. ROS have a dual role in the cell depending on their rate of production. Low or moderate levels of ROS can act as signaling molecules in several physiological processes, however, an overproduction of these reactive species, as occurs in many pathological situations such as AD, leads to the damage of cellular macromolecules and organelles including mitochondria [3741]. It was recently demonstrated that an imbalance in the oxidative status of the triple transgenic mouse model of AD occurs during the Aβ oligomerization period, i.e., before the appearance of Aβ plaques and neurofibrillary tangles, corroborating the notion that oxidative stress is an early event in AD pathology [28,42]. Also, others have shown that mitochondrial dysfunction, translated as bioenergetic deficits, precedes the appearance of pathology in mouse models of AD [43]. Likewise, it has been previously shown that in the brains of AD patients a decrease in cytochrome oxidase (COX) activity, an increase in free radical generation, and a reduction in energy metabolism occur prior to senile plaque formation suggesting that mitochondrial function impairment and oxidative damage are early events in the progression of AD [2732,44]. Oxidative damage occurs when ROS oxidize biomolecules, such as proteins, lipids, or nucleic acids, inducing alterations in their native features which result in the loss of function or gain of deleterious function. Somewhat surprisingly, fewer amyloid plaques are observed in the brains of COX-deficient AD mice when compared with the COX-competent transgenic mice. The reduction in amyloid plaques in the COX-deficient AD mice is accompanied by a reduction in Aβ42 level, β-secretase activity, and oxidative damage [45], with the conclusion that partial defects in COX do not increase oxidative damage nor predispose to the formation of Aβ deposits [45]. Despite these seemingly contradictory findings, several studies point out a number of probable mechanisms to explain how Aβ induces decreased COX activity. Indeed, it has been shown that Aβ is imported into mitochondria by the translocase of the outer membrane (TOM) complex [46], complexes heme groups (critical redox centers found in subunit I of COX) [47,48], and interacts with Aβ-binding alcohol dehydrogenase (ABAD) [49, 50]. Additionally, AβPP has a sequence signal that targets it to mitochondria, blocking the mitochondrial import channels (TOM40 and TIM23) and thus preventing the import of nuclear-encoded complex IV subunits [51]. In line with these data that interconnect mitochondrial respiratory deficits and Aβ neuropathology, it has been recently reported that there is a decreased density (number of mitochondria/µm3 of cytoplasm) of succinic dehydrogenase-positive mitochondria (mitochondrial respiratory complex II) in the CA1 hippocampal region of 3xTg-AD mice [52]. However, it has come to light that Aβ is not the only player which exacerbates mitochondrial dysfunction; indeed it was discovered that Aβ and tau exert synergistic effects in the impairment of oxidative phosphorylation system in 3xTg-AD mice [53].

Mitochondria are also intracellular buffers of cytoplasmic Ca2+ thus having a key role in normal neurotransmission, short- and long-term plasticity, excitotoxicity and regulation of gene transcription, processes highly dependent on Ca2+ levels [18,5460]. Notably, Ca2+ homeostasis is compromised in the presence of Aβ such that Aβ decreases the capacity of mitochondria to accumulate and retain Ca2+ promoting the induction of the permeability transition pore (PTP) [6163]. Moreover, intra-mitochondrial Aβ directly interacts with cyclophilin D (CypD), providing a molecular basis for the Aβ-induced PTP opening [64].

The instability and irreparability of the brain mitochondrial genome allows for the gradual accumulation of mtDNA mutations, especially those induced by oxidative modification, notably oxidative-induced alteration of purines and pyrimidines [1]. Such mtDNA alterations have been linked to an increased incidence of AD [65,66]. In fact, there are many more sporadic mutations in the mtDNA control region in AD patients compared with control cases and several mutations in the mtDNA control region (e.g., T414G, T414C, and T477C) that are unique to AD [66]. The mtDNA control region, the only major noncoding area of the mtDNA, is typically 1122bp in length and regulates and initiates mtDNA replication and transcription [67].

All the mitochondrial function impairments outlined above exacerbate ROS production, creating a positive feedback cycle, pushing cells to an apoptotic “death spiral”. Indeed, high levels of ROS promote the induction of the PTP, a nonselective, high conductance channel, that, when open, allows the release of apoptotic factors such as cytochrome c and the apoptosis-inducing factor (AIF) [68]. A recent study provided evidence of a molecular interaction between AβPP, heat shock proteins and Bcl-2, diminishing their capacity to protect against insults, which is likely to lead to a diverse array of mitochondrial disturbances including apoptosis [69].

Mitochondrial disturbances are undoubtedly associated with the pathogenesis of AD. Since these organelles occupy a strategic position in several cellular processes, it is imperative to maintain a healthy mitochondrial pool within cells, which would be accomplished by the elimination of damaged mitochondria by mitophagy, preserving intact mitochondria. The next sections of this review will be devoted to discussing whether mitochondrial fission/fusion is a process that tags damaged mitochondria to mitophagic elimination and if these processes are efficient in this disease context.


Mitochondria are dynamic organelles that have the ability to divide and fuse with each other. The processes of fission and fusion allow the intermixing of metabolites and mtDNA, the proliferation and distribution of mitochondria, and cellular adaptation to energy demands. This dynamic feature of mitochondria is especially important in polarized cells like neurons, which have a high dependence on energy to maintain their basic physiological functions, such as neurotransmission through the generation of action potentials across the membrane [70]. Mitochondrial fission allows mitochondrial renewal, redistribution, and proliferation into synapses, whereas mitochondrial fusion facilitates mitochondrial movement and distribution across axons into the synapses [33,71,72]. Mitochondrial fusion is suggested as a protective mechanism since it helps maintain sufficient bioenergetic levels in case of injury to individual mitochondria [33,73]; additionally, the fission process is also implicated in the maintenance of a healthy mitochondrial cellular pool, since it allows for the segregation of damaged and inactive mitochondria, a feature observed by a decrease in the levels of optic atrophy 1 (OPA1) protein, thus tagging them for autophagic elimination by a mechanism not fully understood (Fig. 1) [35,74].

Fig. 1
Core molecular machinery involved in the formation of the autophagosome during the autophagic process. Autophagy occurs at basal levels but can also be upregulated by a number of stress signals such as starvation. Moreover, autophagy is negatively modulated ...

A group of GTPases mediates both processes of mitochondrial fission and fusion, however, the mechanisms by which they govern those processes remain to be completely elucidated. Fission-related proteins are dynamin-like protein 1 (DLP1, also referred as Drp1) and Fis1 [2,75]. DLP1 is a member of the conserved dynamin large GTPase superfamily that controls membrane fission, existing constitutively in a cytosolic pool and being recruited to the mitochondrial membrane where it is often detected as a pattern of punctated spots. The putative mechanistic action of DLP1 on mitochondrial membrane relies on the formation of a ring-like complex structure within the mitochondrial surface that constricts the organelle upon the hydrolysis of GTP, initiating fission [76]. Fis1 is a mitochondrial outer membrane protein suggested to act as a receptor for DLP1 [77]. As result of mitochondrial fission, two spherical mitochondria arise [25,70]. Regarding the proteins involved in the process of mitochondrial fusion, three large GTPase proteins assume different functions and ultrastructural locations. For the fusion of the outer membrane to occur, two mitofusins – Mfn1 and Mfn2 – interact by their coiled-coil domains, forming homo- and hetero-oligomeric complexes, thus connecting the mitochondrial outer membranes of close mitochondria [7880]. However, the inner mitochondrial membrane also needs to be fused, and OPA1, being an inner membrane protein that faces the intermembrane space, is implicated in this event, requiring Mfn1, but not Mfn2, to mediate this process [78,81].

Mitochondria divide and fuse in response to several stimuli [25,70], however, the precise mechanisms controlling these events are largely unclear. Some studies have examined post-translational modifications of mitochondrial dynamics-related proteins such as DLP1 and OPA1. DLP1 is known to undergo post-translational modifications such as phosphorylation [8284], ubiquitinylation [85], s-nitrosylation ([86], and sumoylation [87]. Whereas phosphorylation at Ser616 [8284], sumoylation [87], and s-nitrosylation are known to potentiate mitochondrial fission, ubiquitinylation [85] decreases the rate of mitochondrial fission. For mitochondrial fusion to occur, the proteolytic cleavage of OPA1 into long and short isoforms is critical [88]. The machinery that cleaves OPA1 is not completely clear, nevertheless, several proteases of the inner mitochondrial membrane have been associated with its processing [80,81,8890]. However, low mitochondrial ATP levels, the dissipation of the membrane potential across the inner membrane (Δψm), or apoptotic stimuli [89] induce OPA1 cleavage, resulting in the loss of long isoforms, impairing mitochondrial fusion [80,9193].


Macroautophagy is a lysosomal-dependent, self-digestive, evolutionarily-conserved cellular process involved in the degradation of misfolded proteins and damaged organelles, which is also activated in situations of starvation to provide energy to cells. Although this review is not intended to give a detailed analysis on the autophagic pathway, it will provide a brief overview of its core machinery. During autophagy, several cytosolic components are engulfed in double-membrane structures termed autophagic vacuoles (AVs) or autophagosomes [94,95]. Although, in mammals, the origin of these membranes is not completely understood, in yeast, the proposed site for AVs formation is the phagophore assembly site (PAS). Most of the proteins involved in the assembly of the phagophore and its elongation to form an AV are located at the PAS [96,97]. It has been suggested that a possible source of autophagosomal membranes is the trans-Golgi network [98]. The formation of AVs involves a very specific molecular machinery in which only some proteins are shared with the endocytic pathway, such as the Class III phosphatidylinositol 3-kinase. However, during the maturation of AVs they can fuse with endosomes before fusing with the lysosomes [96,98]. The formation of AVs undergoes a multistep process of maturation, such as regulation/nucleation, in which a signal triggers the formation of an isolation membrane called a phagophore. The autophagosome is completely formed when the membrane edges of the phagophore fuse, followed by the last events of the maturation process, which are the dissolution of the inner membrane, fusion with lysosomes, cargo degradation, and release of macromolecules (Fig. 1) [94,95]. During the vesicle nucleation process, two kinases are involved: 1) the Ser/Thr protein kinase mammalian target of rapamycin (mTOR), with an inhibitory action on autophagy, its activity being negatively modulated by rapamycin; and 2) the Class III phosphatidylinositol 3-kinase (Class III PI3K) complex, composed of three highly conserved proteins, the protein kinase vacuolar protein sorting 15 (Vps15), the phosphatidylinositol 3-kinase Vps34, and a modulatory component named Beclin 1/Atg6, with a positive modulatory action on autophagy, where activity is negatively modulated by 3-methyladenine (Fig. 1) [99,100]. Both these molecules act upstream of autophagy-related (Atg) proteins [96,99,101]. The activity of mTOR is positively modulated by the Class I PI3K/Akt pathway [99]. The inhibitory action of mTOR on autophagy is due to the phosphorylation of the regulatory subunit Atg13, disabling its conjugation with Atg1, the yeast homologue of the mammalian unc-51-like kinase 1 (ULK1) (Fig. 1) [102]. Despite this knowledge, very little is known about this branch of the autophagic signaling pathway. Indeed, recently, more proteins were found to belong to this enzymatic complex (for further reading, see [103106]). The role of Class III PI3K in the assembly of AVs is also poorly understood, one suggestion being that the formation of phosphatidylinositol 3-phosphate by Class III PI3K activity enables Atg proteins to bind to the membrane, since these proteins bind to this phospholipid [96,100]. There are two evolutionarily conserved ubiquitin-like conjugation systems of Atg proteins, essential for the vesicle elongation and vesicle completion processes in both yeast and mammals (Fig. 1) [107]. Atg5/Atg12 and Atg16 are one of the conjugation systems and the other is composed by lipidated LC3, the mammalian homologue of yeast Atg8 (Fig. 1) (for further readings, see [108]). Despite the relevance of these proteins in the autophagic process, recent work performed by Nishida and co-workers [109] demonstrated the existence of an alternative process, independent of Atg5, in which the lipidation of LC3 to form LC3-II does not occur. Additionally, the same authors found that this alternative process of autophagy is regulated by several autophagic proteins including ULK1 and Beclin1 [109]. This aside, ultimately, the AV fuses with the lysosome to form the autolysosome, exposing the content of the AV to the action of hydrolases. The fusion process of the AVs to the lysosomes can be inhibited with bafilomycin A1 [110] and requires two families of proteins, the soluble NSF attachment protein receptors (SNAREs) and Rab proteins, specifically, Rab7 (Fig. 1) [111,112].

The term mitophagy was coined by Lemasters to describe the selective degradation of mitochondria by autophagy [113]. Since then, the search for molecular specificities in the process of mitophagic elimination has gained attention [114]. The most exciting reports recently brought together data that suggest a molecular mechanism that tags mitochondria for mitophagy. A screening of several mitophagy-deficient yeast mutants revealed Atg32 as a new protein that is specifically implicated in the selective degradation of mitochondria by mitophagy [115]. Atg32 is an integral membrane protein localized in the mitochondrial outer membrane, docking Atg11, an adaptor protein involved in selective types of autophagy, which subsequently binds Atg8/LC3, recruiting mitochondria to AVs (Fig. 1) [115117]. However several questions remain to be answered such as: What is the mammalian homologue of Atg32? What kind of signals trigger this molecular machinery? In the latter, it has been suggested that Atg32 intramitochondrial motif may be a sensor of mitochondrial dysfunction [117]. In yeast, a number of mitochondrial perturbations were shown to trigger mitophagy such as impairment of the oxidative phosphorylation system [118], loss of cation homeostasis by the alteration of K+/H+ exchanger activity [119], and increased ROS levels, as suggested by the impairment of the reduced glutathione pool [120]. Lemasters group demonstrated in mammalian cells that the induction of autophagy was preceded by the depolarization of mitochondria and PTP opening [113,121,122]. Coenzyme Q10 (CoQ10) deficiency in human fibroblasts was shown to be associated with decreased efficiency in the electron transport chain, decreased Δψm, increased ROS production, and susceptibility to PTP opening, and these features strongly correlate with increased expression of autophagy-related genes, lysosomal markers, and mitophagy [123]. This observation is not surprising since CoQ10, the most predominant form of CoQ in humans, is part of the electron transport chain, accepting electrons from respiratory complexes I and II and has a described antioxidant action [30]. As already discussed, in mammalian cells, depolarized mitochondria fail to undergo fusion and fission events, which target them for mitophagic clearance [35]. Indeed, inhibition of autophagy results in decreased Δψm and fusion arrestment in rat myoblasts and human fibroblasts [124].

Altogether, these observations suggest that fission/fusion events exert a protective effect against mitochondrial dysfunction through the segregation of damaged components into a mitochondrion that undergoes mitophagy.


AD brains show ultrastructural alterations in mitochondrial morphology such as reduced size and broken internal membrane cristae [125,126]. Moreover, it is recognized that mitophagy exerts protective effects in a number of deleterious situations, such as CoQ10 deficiency [123], hypoxia [127], and rotenone exposure [128]. Little is known about mitophagy in AD brains; however, it is known that autophagy loses efficiency with the progression of the disease, mainly through a decrease in the efficiency of the lysosomal system [129133]. As discussed previously, mTOR activity can be positively modulated by the Class I PI3K/Akt pathway. This pathway, which affects the autophagic pathway, has also been shown to be affected in AD. While some studies show that Aβ reduces Akt activity and that elevating its activity rescues cell death [134], others show that Aβ upregulates Akt phosphorylation [135]. More recently, in a Drosophila genetic model of AD that overexpresses Aβ, it was demonstrated that Aβ stimulates Class I PI3K activity [136]. Importantly, an increase in Akt activity is found in the temporal cortex of postmortem AD brains suggesting an upregulation of the Class I PI3K/Akt pathway in patients [137140] and increased phosphorylation of the Akt substrate mTOR [137,141,142]. Evidence showing mitophagy in AD is very scarce; however, Moreira and coworkers [143,144] showed that there is increased mitochondrial autophagy in AD. Nevertheless several questions are still unanswered: 1) Are sequestered mitochondria in AVs being efficiently delivered to lysosomal degradation?; 2) Is increased mitophagy being protective?; 3) Does the process begin at the early stages of disease, or does it start too late to render protection to the cells?; 4) What tags damaged mitochondria for degradation, or is mitophagy not selective to damaged mitochondria?

The first and the latter questions are already being examined and answered. Based on previously discussed subjects, it is expected that despite increased mitochondria sequestration in AVs, they are probably not being efficiently degraded. Also since there are indications that mitochondrial fission and selective fusion direct the elimination of damaged mitochondria (Fig. 1) [35], it is expected that the same happens in AD. Indeed, Wang and coworkers determined the state of mitochondrial fission/fusion events in fibroblasts from sporadic AD patients [145,146] and M17 neuroblastoma cells overexpressing the Swedish variant of AβPP (AβPPswe) [147]. The imbalance induced by Aβ in mitochondrial fission/fusion proteins occurs either by post-translational modification, such as S-nitrosylation [86], or by alteration of their expression [145147]. Whereas it is reported in fibroblasts from sporadic AD patients that DLP1 protein levels are decreased, thus impairing fission, which is translated into the development of elongated mitochondria [145, 146], at the same time it is described in M17 neuroblastoma cells overexpressing AβPPswe that besides decreased levels of DLP1, OPA1 proteins levels are decreased and Fis1 levels increased [147]. AβPP overexpression further induces a severe mitochondrial fragmentation phenotype in both M17 and primary hippocampal neurons, concomitantly with a reduction in the number of mitochondria [147]. Altogether these data suggest that mitochondrial fission is upregulated, probably in an attempt to segregate damaged mitochondria to degradation by mitophagy, which is in agreement with the observation of reduced mitochondrial number [125]. However, the destination of these fissioned mitochondria to mitophagy needs to be further clarified and more importantly, the hypothesis that mitophagy is not efficient due to an impairment of the lysosomal system remains to be addressed.


Mitochondrial dysfunction is now consensually accepted as being a feature in AD brain, however, whether it is an early causal event or a consequence of other neuropathological events remains under intense debate. Maintaining a large number of healthy mitochondria in cells is critical to cellular survival since these organelles occupy a strategic position in several key cellular processes. This is particularly important in cells with high energetic demands such as neurons. It has been observed that mitochondria are highly dynamic organelles, dividing and fusing with each other. Both fission and fusion processes have been established as beneficial, responding to reestablish energetic levels in case of an injury to individual mitochondria or by segregating damaged mitochondrial components to a single mitochondrion that is tagged to undergo mitophagy. The role of mitophagy in AD is not currently understood, and it is unclear whether mitochondria are eventually degraded or if the process fails to efficiently eliminate mitochondria. Further knowledge about these mitochondrial events in AD will hopefully provide a window for therapeutic intervention targeting improvements in mitochondrial function.


Work in the authors’ laboratories is supported by the National Institutes of Health (AG024028 and AG031852) and the Alzheimer’s Association.


Authors’ disclosures available online (


1. Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010;362:329–344. [PubMed]
2. Su B, Wang X, Bonda D, Perry G, Smith M, Zhu X. Abnormal mitochondrial dynamics-a novel therapeutic target for Alzheimer’s disease? Mol Neurobiol. 2010 in press. [PMC free article] [PubMed]
3. Smith MA. Alzheimer disease. Int Rev Neurobiol. 1998;42:1–54. [PubMed]
4. Slow EJ, Graham RK, Hayden MR. To be or not to be toxic: aggregations in Huntington and Alzheimer disease. Trends Genet. 2006;22:408–411. [PubMed]
5. Glabe CG, Kayed R. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology. 2006;66:S74–S78. [PubMed]
6. Swerdlow RH, Khan SM. A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease. Med Hypotheses. 2004;63:8–20. [PubMed]
7. Swerdlow RH, Khan SM. The Alzheimer’s disease mitochondrial cascade hypothesis: an update. Exp Neurol. 2009;218:308–315. [PMC free article] [PubMed]
8. Hauptmann S, Scherping I, Drose S, Brandt U, Schulz KL, Jendrach M, Leuner K, Eckert A, Muller WE. Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging. 2009;30:1574–1586. [PubMed]
9. Smith MA, Sayre LM, Monnier VM, Perry G. Radical AGEing in Alzheimer’s disease. Trends Neurosci. 1995;18:172–176. [PubMed]
10. Humpel C, Marksteiner J. Cerebrovascular damage as a cause for Alzheimer’s disease. Curr Neurovasc Res. 2005;2:341–347. [PubMed]
11. Brenner SR. Neurovascular unit dysfunction: a vascular component of Alzheimer disease? Neurology. 2008;70:243–244. [PubMed]
12. Pei JJ, Sjogren M, Winblad B. Neurofibrillary degeneration in Alzheimer’s disease: from molecular mechanisms to identification of drug targets. Curr Opin Psychiatry. 2008;21:555–561. [PubMed]
13. Lee HG, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X, Takeda A, Nunomura A, Smith MA. Tau phosphorylation in Alzheimer’s disease: pathogen or protector? Trends Mol Med. 2005;11:164–169. [PubMed]
14. Chung SH. Aberrant phosphorylation in the pathogenesis of Alzheimer’s disease. BMB Rep. 2009;42:467–474. [PubMed]
15. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356. [PubMed]
16. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101–112. [PubMed]
17. Korczyn AD. The amyloid cascade hypothesis. Alzheimers Dement. 2008;4:176–178. [PubMed]
18. Celsi F, Pizzo P, Brini M, Leo S, Fotino C, Pinton P, Rizzuto R. Mitochondria, calcium and cell death: a deadly triad in neurodegeneration. Biochim Biophys Acta. 2009;1787:335–344. [PMC free article] [PubMed]
19. Newmeyer DD, Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell. 2003;112:481–490. [PubMed]
20. Moreira PI, Duarte AI, Santos MS, Rego AC, Oliveira CR. An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer’s disease. J Alzheimers Dis. 2009;16:741–761. [PubMed]
21. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell. 2005;120:483–495. [PubMed]
22. Wei YH, Wu SB, Ma YS, Lee HC. Respiratory function decline and DNA mutation in mitochondria, oxidative stress and altered gene expression during aging. Chang Gung Med J. 2009;32:113–132. [PubMed]
23. Harman D. The free radical theory of aging. Antioxid Redox Signal. 2003;5:557–561. [PubMed]
24. Kann O, Kovacs R. Mitochondria and neuronal activity. Am J Physiol Cell Physiol. 2007;292:C641–C657. [PubMed]
25. Chan DC. Mitochondria: dynamic organelles in disease, aging, and development. Cell. 2006;125:1241–1252. [PubMed]
26. Blass JP. The mitochondrial spiral. An adequate cause of dementia in the Alzheimer’s syndrome. Ann N Y Acad Sci. 2000;924:170–183. [PubMed]
27. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787–795. [PubMed]
28. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001;60:759–767. [PubMed]
29. Reddy PH, Beal MF. Are mitochondria critical in the pathogenesis of Alzheimer’s disease? Brain Res Brain Res Rev. 2005;49:618–632. [PubMed]
30. Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G. Mitochondrial dysfunction is a trigger of Alzheimer’s disease pathophysiology. Biochim Biophys Acta. 2010;1802:2–10. [PubMed]
31. Parker WD., Jr Cytochrome oxidase deficiency in Alzheimer’s disease. Ann N Y Acad Sci. 1991;640:59–64. [PubMed]
32. Maurer I, Zierz S, Moller HJ. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol Aging. 2000;21:455–462. [PubMed]
33. Chen H, McCaffery JM, Chan DC. Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell. 2007;130:548–562. [PubMed]
34. Cheng X, Kanki T, Fukuoh A, Ohgaki K, Takeya R, Aoki Y, Hamasaki N, Kang D. PDIP38 Associates with Proteins Constituting the Mitochondrial DNA Nucleoid. J Biochem (Tokyo) 2005;138:673–678. [PubMed]
35. Twig G, Elorza A, Molina AJ, Mohamed H, Wikstrom JD, Walzer G, Stiles L, Haigh SE, Katz S, Las G, Alroy J, Wu M, Py BF, Yuan J, Deeney JT, Corkey BE, Shirihai OS. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J. 2008;27:433–446. [PubMed]
36. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417:1–13. [PMC free article] [PubMed]
37. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39:44–84. [PubMed]
38. Droge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002;82:47–95. [PubMed]
39. Afanas’ev IB. Signaling functions of free radicals superoxide & nitric oxide under physiological & pathological conditions. Mol Biotechnol. 2007;37:2–4. [PubMed]
40. Addabbo F, Montagnani M, Goligorsky MS. Mitochondria and reactive oxygen species. Hypertension. 2009;53:885–892. [PMC free article] [PubMed]
41. Starkov AA. The role of mitochondria in reactive oxygen species metabolism and signaling. Ann N Y Acad Sci. 2008;1147:37–52. [PMC free article] [PubMed]
42. Resende R, Moreira PI, Proenca T, Deshpande A, Busciglio J, Pereira C, Oliveira CR. Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. Free Radic Biol Med. 2008;44:2051–2057. [PubMed]
43. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer’s pathology in female mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2009;106:14670–14675. [PubMed]
44. Russell RL, Siedlak SL, Raina AK, Bautista JM, Smith MA, Perry G. Increased neuronal glucose-6-phosphate dehydrogenase and sulfhydryl levels indicate reductive compensation to oxidative stress in Alzheimer disease. Arch Biochem Biophys. 1999;370:236–239. [PubMed]
45. Fukui H, Diaz F, Garcia S, Moraes CT. Cytochrome c oxidase deficiency in neurons decreases both oxidative stress and amyloid formation in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2007;104:14163–14168. [PubMed]
46. Hansson Petersen CA, Alikhani N, Behbahani H, Wiehager B, Pavlov PF, Alafuzoff I, Leinonen V, Ito A, Winblad B, Glaser E, Ankarcrona M. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci U S A. 2008;105:13145–13150. [PubMed]
47. Atamna H, Frey WH., 2nd A role for heme in Alzheimer’s disease: heme binds amyloid beta and has altered metabolism. Proc Natl Acad Sci U S A. 2004;101:11153–11158. [PubMed]
48. Atamna H. Heme binding to Amyloid-beta peptide: mechanistic role in Alzheimer’s disease. J Alzheimers Dis. 2006;10:255–266. [PubMed]
49. Takuma K, Yao J, Huang J, Xu H, Chen X, Luddy J, Trillat AC, Stern DM, Arancio O, Yan SS. ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB J. 2005;19:597–598. [PubMed]
50. Dell’agnello C, Leo S, Agostino A, Szabadkai G, Tiveron C, Zulian A, Prelle A, Roubertoux P, Rizzuto R, Zeviani M. Increased longevity and refractoriness to Ca(2+)-dependent neurodegeneration in Surf1 knockout mice. Hum Mol Genet. 2007;16:431–444. [PubMed]
51. Devi L, Prabhu BM, Galati DF, Avadhani NG, Anandatheerthavarada HK. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer’s disease brain is associated with mitochondrial dysfunction. J Neurosci. 2006;26:9057–9068. [PubMed]
52. Fattoretti P, Balietti M, Casoli T, Giorgetti B, Di Stefano G, Bertoni-Freddari C, Lattanzio F, Sensi SL. Decreased numeric density of succinic dehydrogenase-positive mitochondria in CA1 pyramidal neurons of 3xTg-AD mice. Rejuvenation Res. 2010;13:144–147. [PubMed]
53. Rhein V, Song X, Wiesner A, Ittner LM, Baysang G, Meier F, Ozmen L, Bluethmann H, Drose S, Brandt U, Savaskan E, Czech C, Gotz J, Eckert A. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer’s disease mice. Proc Natl Acad Sci U S A. 2009;106:20057–20062. [PubMed]
54. Rizzuto R, Bernardi P, Pozzan T. Mitochondria as all-round players of the calcium game. J Physiol. 2000;529(Pt 1):37–47. [PubMed]
55. Zimmermann H. Neurotransmitter release. FEBS Lett. 1990;268:394–399. [PubMed]
56. Rizzuto R, Pinton P, Brini M, Chiesa A, Filippin L, Pozzan T. Mitochondria as biosensors of calcium microdomains. Cell Calcium. 1999;26:193–199. [PubMed]
57. Zucker RS. Calcium- and activity-dependent synaptic plasticity. Curr Opin Neurobiol. 1999;9:305–313. [PubMed]
58. Soderling TR. CaM-kinases: modulators of synaptic plasticity. Curr Opin Neurobiol. 2000;10:375–380. [PubMed]
59. Sabatini BL, Maravall M, Svoboda K. Ca(2+) signaling in dendritic spines. Curr Opin Neurobiol. 2001;11:349–356. [PubMed]
60. Wojda U, Salinska E, Kuznicki J. Calcium ions in neuronal degeneration. IUBMB Life. 2008;60:575–590. [PubMed]
61. Moreira PI, Santos MS, Moreno A, Oliveira C. Amyloid beta-peptide promotes permeability transition pore in brain mitochondria. Biosci Rep. 2001;21:789–800. [PubMed]
62. Moreira PI, Santos MS, Moreno A, Rego AC, Oliveira C. Effect of amyloid beta-peptide on permeability transition pore: a comparative study. J Neurosci Res. 2002;69:257–267. [PubMed]
63. Moreira PI, Santos MS, Moreno AM, Seica R, Oliveira CR. Increased vulnerability of brain mitochondria in diabetic (Goto-Kakizaki) rats with aging and amyloid-beta exposure. Diabetes. 2003;52:1449–1456. [PubMed]
64. Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM, Yan Y, Wang C, Zhang H, Molkentin JD, Gunn-Moore FJ, Vonsattel JP, Arancio O, Chen JX, Yan SD. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer’s disease. Nat Med. 2008;14:1097–1105. [PMC free article] [PubMed]
65. Wallace DC, Stugard C, Murdock D, Schurr T, Brown MD. Ancient mtDNA sequences in the human nuclear genome: a potential source of errors in identifying pathogenic mutations. Proc Natl Acad Sci U S A. 1997;94:14900–14905. [PubMed]
66. Coskun PE, Beal MF, Wallace DC. Alzheimer’s brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci U S A. 2004;101:10726–10731. [PubMed]
67. Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith AJ, Staden R, Young IG. Sequence and organization of the human mitochondrial genome. Nature. 1981;290:457–465. [PubMed]
68. Ribe EM, Serrano-Saiz E, Akpan N, Troy CM. Mechanisms of neuronal death in disease: defining the models and the players. Biochem J. 2008;415:165–182. [PubMed]
69. Yang TT, Hsu CT, Kuo YM. Amyloid precursor protein, heat-shock proteins, and Bcl-2 form a complex in mitochondria and modulate mitochondria function and apoptosis in N2a cells. Mech Ageing Dev. 2009;130:592–601. [PubMed]
70. Knott AB, Perkins G, Schwarzenbacher R, Bossy-Wetzel E. Mitochondrial fragmentation in neurodegeneration. Nat Rev Neurosci. 2008;9:505–518. [PMC free article] [PubMed]
71. Baloh RH, Schmidt RE, Pestronk A, Milbrandt J. Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations. J Neurosci. 2007;27:422–430. [PubMed]
72. Hoppins S, Lackner L, Nunnari J. The machines that divide and fuse mitochondria. Annu Rev Biochem. 2007;76:751–780. [PubMed]
73. Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol. 2003;160:189–200. [PMC free article] [PubMed]
74. Barsoum MJ, Yuan H, Gerencser AA, Liot G, Kushnareva Y, Graber S, Kovacs I, Lee WD, Waggoner J, Cui J, White AD, Bossy B, Martinou JC, Youle RJ, Lipton SA, Ellisman MH, Perkins GA, Bossy-Wetzel E. Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons. EMBO J. 2006;25:3900–3911. [PubMed]
75. Su B, Wang X, Zheng L, Perry G, Smith MA, Zhu X. Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochim Biophys Acta. 2010;1802:135–142. [PMC free article] [PubMed]
76. Smirnova E, Griparic L, Shurland DL, van der Bliek AM. Dynamin-related protein Drp1 is required for mitochondrial division in mammalian cells. Mol Biol Cell. 2001;12:2245–2256. [PMC free article] [PubMed]
77. James DI, Parone PA, Mattenberger Y, Martinou JC. hFis1, a novel component of the mammalian mitochondrial fission machinery. J Biol Chem. 2003;278:36373–36379. [PubMed]
78. Chen H, Chomyn A, Chan DC. Disruption of fusion results in mitochondrial heterogeneity and dysfunction. J Biol Chem. 2005;280:26185–26192. [PubMed]
79. Zuchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, Zappia M, Nelis E, Patitucci A, Senderek J, Parman Y, Evgrafov O, Jonghe PD, Takahashi Y, Tsuji S, Pericak-Vance MA, Quattrone A, Battaloglu E, Polyakov AV, Timmerman V, Schroder JM, Vance JM. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet. 2004;36:449–451. [PubMed]
80. Ishihara N, Fujita Y, Oka T, Mihara K. Regulation of mitochondrial morphology through proteolytic cleavage of OPA1. EMBO J. 2006;25:2966–2977. [PubMed]
81. Cipolat S, Martins de Brito O, Dal Zilio B, Scorrano L. OPA1 requires mitofusin 1 to promote mitochondrial fusion. Proc Natl Acad Sci U S A. 2004;101:15927–15932. [PubMed]
82. Chang CR, Blackstone C. Cyclic AMP-dependent protein kinase phosphorylation of Drp1 regulates its GTPase activity and mitochondrial morphology. J Biol Chem. 2007;282:21583–21587. [PubMed]
83. Cribbs JT, Strack S. Reversible phosphorylation of Drp1 by cyclic AMP-dependent protein kinase and calcineurin regulates mitochondrial fission and cell death. EM-BO Rep. 2007;8:939–944. [PubMed]
84. Taguchi N, Ishihara N, Jofuku A, Oka T, Mihara K. Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in mitochondrial fission. J Biol Chem. 2007;282:11521–11529. [PubMed]
85. Nakamura N, Kimura Y, Tokuda M, Honda S, Hirose S. MARCH-V is a novel mitofusin 2- and Drp1-binding protein able to change mitochondrial morphology. EMBO Rep. 2006;7:1019–1022. [PubMed]
86. Cho DH, Nakamura T, Fang J, Cieplak P, Godzik A, Gu Z, Lipton SA. S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science. 2009;324:102–105. [PMC free article] [PubMed]
87. Harder Z, Zunino R, McBride H. Sumo1 conjugates mitochondrial substrates and participates in mitochondrial fission. Curr Biol. 2004;14:340–345. [PubMed]
88. Song Z, Chen H, Fiket M, Alexander C, Chan DC. OPA1 processing controls mitochondrial fusion and is regulated by mRNA splicing, membrane potential, and Yme1L. J Cell Biol. 2007;178:749–755. [PMC free article] [PubMed]
89. Griparic L, Kanazawa T, van der Bliek AM. Regulation of the mitochondrial dynamin-like protein Opa1 by proteolytic cleavage. J Cell Biol. 2007;178:757–764. [PMC free article] [PubMed]
90. Ehses S, Raschke I, Mancuso G, Bernacchia A, Geimer S, Tondera D, Martinou JC, Westermann B, Rugarli EI, Langer T. Regulation of OPA1 processing and mitochondrial fusion by m-AAA protease isoenzymes and OMA1. J Cell Biol. 2009;187:1023–1036. [PMC free article] [PubMed]
91. Duvezin-Caubet S, Jagasia R, Wagener J, Hofmann S, Trifunovic A, Hansson A, Chomyn A, Bauer MF, Attardi G, Larsson NG, Neupert W, Reichert AS. Proteolytic processing of OPA1 links mitochondrial dysfunction to alterations in mitochondrial morphology. J Biol Chem. 2006;281:37972–37979. [PubMed]
92. Baricault L, Segui B, Guegand L, Olichon A, Valette A, Larminat F, Lenaers G. OPA1 cleavage depends on decreased mitochondrial ATP level and bivalent metals. Exp Cell Res. 2007;313:3800–3808. [PubMed]
93. Guillery O, Malka F, Landes T, Guillou E, Blackstone C, Lombes A, Belenguer P, Arnoult D, Rojo M. Metalloprotease-mediated OPA1 processing is modulated by the mitochondrial membrane potential. Biol Cell. 2008;100:315–325. [PubMed]
94. Cherra SJ, Chu CT. Autophagy in neuroprotection and neurodegeneration: A question of balance. Future Neurol. 2008;3:309–323. [PMC free article] [PubMed]
95. Chu CT. Autophagic stress in neuronal injury and disease. J Neuropathol Exp Neurol. 2006;65:423–432. [PMC free article] [PubMed]
96. Xie Z, Klionsky DJ. Autophagosome formation: core machinery and adaptations. Nat Cell Biol. 2007;9:1102–1109. [PubMed]
97. Yang Z, Klionsky DJ. Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol. 2010;22:124–131. [PMC free article] [PubMed]
98. Hamasaki M, Yoshimori T. Where do they come from? Insights into autophagosome formation. FEBS Lett. 2010;584:1296–1301. [PubMed]
99. Pattingre S, Espert L, Biard-Piechaczyk M, Codogno P. Regulation of macroautophagy by mTOR and Beclin 1 complexes. Biochimie. 2008;90:313–323. [PubMed]
100. Todde V, Veenhuis M, van der Klei IJ. Autophagy: principles and significance in health and disease. Biochim Biophys Acta. 2009;1792:3–13. [PubMed]
101. Eskelinen EL. New insights into the mechanisms of macroautophagy in mammalian cells. Int Rev Cell Mol Biol. 2008;266:207–247. [PubMed]
102. Kamada Y, Funakoshi T, Shintani T, Nagano K, Ohsumi M, Ohsumi Y. Tor-mediated induction of autophagy via an Apg1 protein kinase complex. J Cell Biol. 2000;150:1507–1513. [PMC free article] [PubMed]
103. Hara T, Mizushima N. Role of ULK-FIP200 complex in mammalian autophagy: FIP200, a counterpart of yeast Atg17? Autophagy. 2009;5:85–87. [PubMed]
104. Hosokawa N, Sasaki T, Iemura S, Natsume T, Hara T, Mizushima N. Atg101, a novel mammalian autophagy protein interacting with Atg13. Autophagy. 2009;5:973–979. [PubMed]
105. Mercer CA, Kaliappan A, Dennis PB. A novel, human Atg13 binding protein, Atg101, interacts with ULK1 and is essential for macroautophagy. Autophagy. 2009;5:649–662. [PubMed]
106. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11:329–341. [PubMed]
107. Kundu M, Thompson CB. Autophagy: basic principles and relevance to disease. Annu Rev Pathol. 2008;3:427–455. [PubMed]
108. Reggiori F. 1. Membrane origin for autophagy. Curr Top Dev Biol. 2006;74:1–30. [PubMed]
109. Nishida Y, Arakawa S, Fujitani K, Yamaguchi H, Mizuta T, Kanaseki T, Komatsu M, Otsu K, Tsujimoto Y, Shimizu S. Discovery of Atg5/Atg7-independent alternative macroautophagy. Nature. 2009;461:654–658. [PubMed]
110. Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R, Tashiro Y. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct. 1998;23:33–42. [PubMed]
111. Jager S, Bucci C, Tanida I, Ueno T, Kominami E, Saftig P, Eskelinen EL. Role for Rab7 in maturation of late autophagic vacuoles. J Cell Sci. 2004;117:4837–4848. [PubMed]
112. Eskelinen EL. Maturation of autophagic vacuoles in Mammalian cells. Autophagy. 2005;1:1–10. [PubMed]
113. Lemasters JJ. Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. Rejuvenation Res. 2005;8:3–5. [PubMed]
114. Tolkovsky AM. Mitophagy. Biochim Biophys Acta. 2009;1793:1508–1515. [PubMed]
115. Kanki T, Wang K, Cao Y, Baba M, Klionsky DJ. Atg32 is a mitochondrial protein that confers selectivity during mitophagy. Dev Cell. 2009;17:98–109. [PMC free article] [PubMed]
116. Kanki T, Klionsky DJ. Mitophagy in yeast occurs through a selective mechanism. J Biol Chem. 2008;283:32386–32393. [PMC free article] [PubMed]
117. Okamoto K, Kondo-Okamoto N, Ohsumi Y. Mitochondria-anchored receptor Atg32 mediates degradation of mitochondria via selective autophagy. Dev Cell. 2009;17:87–97. [PubMed]
118. Priault M, Salin B, Schaeffer J, Vallette FM, di Rago JP, Martinou JC. Impairing the bioenergetic status and the biogenesis of mitochondria triggers mitophagy in yeast. Cell Death Differ. 2005;12:1613–1621. [PubMed]
119. Nowikovsky K, Reipert S, Devenish RJ, Schweyen RJ. Mdm38 protein depletion causes loss of mitochondrial K+/H+ exchange activity, osmotic swelling and mitophagy. Cell Death Differ. 2007;14:1647–1656. [PubMed]
120. Deffieu M, Bhatia-Kissova I, Salin B, Galinier A, Manon S, Camougrand N. Glutathione participates in the regulation of mitophagy in yeast. J Biol Chem. 2009;284:14828–14837. [PMC free article] [PubMed]
121. Elmore SP, Qian T, Grissom SF, Lemasters JJ. The mitochondrial permeability transition initiates autophagy in rat hepatocytes. FASEB J. 2001;15:2286–2287. [PubMed]
122. Kim I, Rodriguez-Enriquez S, Lemasters JJ. Selective degradation of mitochondria by mitophagy. Arch Biochem Biophys. 2007;462:245–253. [PMC free article] [PubMed]
123. Rodriguez-Hernandez A, Cordero MD, Salviati L, Artuch R, Pineda M, Briones P, Gomez Izquierdo L, Cotan D, Navas P, Sanchez-Alcazar JA. Coenzyme Q deficiency triggers mitochondria degradation by mitophagy. Autophagy. 2009;5:19–32. [PubMed]
124. Navratil M, Terman A, Arriaga EA. Giant mitochondria do not fuse and exchange their contents with normal mitochondria. Exp Cell Res. 2008;314:164–172. [PubMed]
125. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, At-wood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G, Smith MA. Mitochondrial abnormalities in Alzheimer’s disease. J Neurosci. 2001;21:3017–3023. [PubMed]
126. Baloyannis SJ. Mitochondrial alterations in Alzheimer’s disease. J Alzheimers Dis. 2006;9:119–126. [PubMed]
127. Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, Wesley JB, Gonzalez FJ, Semenza GL. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem. 2008;283:10892–10903. [PMC free article] [PubMed]
128. Pan T, Rawal P, Wu Y, Xie W, Jankovic J, Le W. Rapamycin protects against rotenone-induced apoptosis through autophagy induction. Neuroscience. 2009;164:541–551. [PubMed]
129. Ditaranto K, Tekirian TL, Yang AJ. Lysosomal membrane damage in soluble Abeta-mediated cell death in Alzheimer’s disease. Neurobiol Dis. 2001;8:19–31. [PubMed]
130. Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, Nixon RA. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer’s disease. J Neurosci. 2008;28:6926–6937. [PMC free article] [PubMed]
131. Ling D, Song HJ, Garza D, Neufeld TP, Salvaterra PM. Abeta42-induced neurodegeneration via an age-dependent autophagic-lysosomal injury in Drosophila. PLoS One. 2009;4:e4201. [PMC free article] [PubMed]
132. Zheng L, Kagedal K, Dehvari N, Benedikz E, Cowburn R, Marcusson J, Terman A. Oxidative stress induces macroautophagy of amyloid beta-protein and ensuing apoptosis. Free Radic Biol Med. 2009;46:422–429. [PubMed]
133. Yang AJ, Chandswangbhuvana D, Margol L, Glabe CG. Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1–42 pathogenesis. J Neurosci Res. 1998;52:691–698. [PubMed]
134. Ma R, Xiong N, Huang C, Tang Q, Hu B, Xiang J, Li G. Erythropoietin protects PC12 cells from beta-amyloid(25–35)-induced apoptosis via PI3K/Akt signaling pathway. Neuropharmacology. 2009;56:1027–1034. [PubMed]
135. Abbott JJ, Howlett DR, Francis PT, Williams RJ. Abeta(1–42) modulation of Akt phosphorylation via alpha7 nAChR and NMDA receptors. Neurobiol Aging. 2008;29:992–1001. [PubMed]
136. Chiang HC, Wang L, Xie Z, Yau A, Zhong Y. PI3 kinase signaling is involved in Abeta-induced memory loss in Drosophila. Proc Natl Acad Sci U S A. 2010;107:7060–7065. [PubMed]
137. Griffin RJ, Moloney A, Kelliher M, Johnston JA, Ravid R, Dockery P, O’Connor R, O’Neill C. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer’s disease pathology. J Neurochem. 2005;93:105–117. [PubMed]
138. Rickle A, Bogdanovic N, Volkmann I, Zhou X, Pei JJ, Winblad B, Cowburn RF. PTEN levels in Alzheimer’s disease medial temporal cortex. Neurochem Int. 2006;48:114–123. [PubMed]
139. Nakagami Y. Inhibitors beta-amyloid-induced toxicity by modulating the Akt signaling pathway. Drug News Perspect. 2004;17:655–660. [PubMed]
140. Rickle A, Bogdanovic N, Volkman I, Winblad B, Ravid R, Cowburn RF. Akt activity in Alzheimer’s disease and other neurodegenerative disorders. Neuroreport. 2004;15:955–959. [PubMed]
141. Li X, Alafuzoff I, Soininen H, Winblad B, Pei JJ. Levels of mTOR and its downstream targets 4E–BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer’s disease brain. FEBS J. 2005;272:4211–4220. [PubMed]
142. An WL, Cowburn RF, Li L, Braak H, Alafuzoff I, Iqbal K, Iqbal IG, Winblad B, Pei JJ. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer’s disease. Am J Pathol. 2003;163:591–607. [PubMed]
143. Moreira PI, Siedlak SL, Wang X, Santos MS, Oliveira CR, Tabaton M, Nunomura A, Szweda LI, Aliev G, Smith MA, Zhu X, Perry G. Increased autophagic degradation of mitochondria in Alzheimer disease. Autophagy. 2007;3:614–615. [PubMed]
144. Moreira PI, Siedlak SL, Wang X, Santos MS, Oliveira CR, Tabaton M, Nunomura A, Szweda LI, Aliev G, Smith MA, Zhu X, Perry G. Autophagocytosis of mitochondria is prominent in Alzheimer disease. J Neuropathol Exp Neurol. 2007;66:525–532. [PubMed]
145. Wang X, Su B, Fujioka H, Zhu X. Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer’s disease patients. Am J Pathol. 2008;173:470–482. [PubMed]
146. Wang X, Su B, Zheng L, Perry G, Smith MA, Zhu X. The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer’s disease. J Neurochem. 2009;109 Suppl 1:153–159. [PMC free article] [PubMed]
147. Wang X, Su B, Siedlak SL, Moreira PI, Fujioka H, Wang Y, Casadesus G, Zhu X. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci U S A. 2008;105:19318–19323. [PubMed]